688621 Stock Overview
A contract research company, engages in the research and development of drugs in China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥30.70 |
| 52 Week High | CN¥75.78 |
| 52 Week Low | CN¥30.03 |
| Beta | 0.012 |
| 11 Month Change | -19.17% |
| 3 Month Change | -37.40% |
| 1 Year Change | -45.66% |
| 33 Year Change | -60.57% |
| 5 Year Change | n/a |
| Change since IPO | -64.21% |
Recent News & Updates
Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance
Sep 05
Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Jul 31We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt
May 29Recent updates
Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance
Sep 05Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)
Jul 31We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt
May 29Shareholder Returns
| 688621 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -9.0% | -2.7% | -2.4% |
| 1Y | -45.7% | -41.4% | -20.1% |
Return vs Industry: 688621 underperformed the CN Life Sciences industry which returned -41.4% over the past year.
Return vs Market: 688621 underperformed the CN Market which returned -20.1% over the past year.
Price Volatility
| 688621 volatility | |
|---|---|
| 688621 Average Weekly Movement | 7.5% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 688621's share price has been volatile over the past 3 months.
Volatility Over Time: 688621's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 1,370 | Yujing Liu | www.sun-novo.com |
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Fundamentals Summary
| 688621 fundamental statistics | |
|---|---|
| Market cap | CN¥3.44b |
| Earnings (TTM) | CN¥215.33m |
| Revenue (TTM) | CN¥1.03b |
16.0x
P/E Ratio3.3x
P/S RatioIs 688621 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688621 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.03b |
| Cost of Revenue | CN¥452.92m |
| Gross Profit | CN¥581.02m |
| Other Expenses | CN¥365.68m |
| Earnings | CN¥215.33m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.92 |
| Gross Margin | 56.19% |
| Net Profit Margin | 20.83% |
| Debt/Equity Ratio | 41.1% |
How did 688621 perform over the long term?
See historical performance and comparison